series-a
Stage
1
Investors
About
Santero is a biotech spin-off from the Université libre de Bruxelles developing first-in-class small molecule antibiotics that target bacterial dormancy mechanisms to treat chronic, multi-drug resistant infections and restore the effectiveness of existing therapies.
Explore Santero's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.